Shots:

• The companies collaborated to evaluate TPST-1120 + Tecentriq (atezolizumab) and Avastin (bevacizumab) in P-Ib/II study in ~60 patients with advanced HCC prior not treated with HCC
• Tempest will retain the global rights to develop & commercialize TPST-1120 while Roche will manage the study operations for a global study
• TPST-1120 is a first-in-class selective PPAR⍺ antagonist with a two-pronged mechanism designed to target both tumor cells directly and suppressive immune cells in the tumor microenvironment. In extensive non-clinical studies- TPST-1120 as a monothx. or in combination with other drugs resulted in reductions of tumor growth and stimulation of durable anti-tumor immunity

 ­ Ref: Globe Newswire | Image: Roche